IS7936A - Pýrasóló[1,5-A][1,3,5]tríasín afleiður sem kannabinóíð viðtaka bindlar - Google Patents

Pýrasóló[1,5-A][1,3,5]tríasín afleiður sem kannabinóíð viðtaka bindlar

Info

Publication number: IS7936A
Authority: IS; Iceland
Prior art keywords: pyrazolo; triazine derivatives; cannabinoid receptors; bind; bind cannabinoid
Prior art date: 2003-02-06

Application number

IS7936A

Other languages

English (en)

Inventor

Andrew Griffith David

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-06

Filing date

2005-07-11

Publication date

2005-07-11

2005-07-11 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-07-11 Publication of IS7936A publication Critical patent/IS7936A/is

Links

102000018208 Cannabinoid Receptor Human genes 0.000 title 1
108050007331 Cannabinoid receptor Proteins 0.000 title 1
JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical class N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Pregnancy & Childbirth (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS7936A 2003-02-06 2005-07-11 Pýrasóló[1,5-A][1,3,5]tríasín afleiður sem kannabinóíð viðtaka bindlar IS7936A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44572803P	2003-02-06	2003-02-06
PCT/IB2004/000269 WO2004069837A1 (en)	2003-02-06	2004-01-26	Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands

Publications (1)

Publication Number	Publication Date
IS7936A true IS7936A (is)	2005-07-11

Family

ID=32851000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7936A IS7936A (is)	2003-02-06	2005-07-11	Pýrasóló[1,5-A][1,3,5]tríasín afleiður sem kannabinóíð viðtaka bindlar

Country Status (29)

Country	Link
US (1)	US7329658B2 (is)
EP (1)	EP1592691A1 (is)
JP (1)	JP4018736B2 (is)
KR (1)	KR20050099531A (is)
CN (1)	CN1768061A (is)
AP (1)	AP2005003368A0 (is)
AR (1)	AR043038A1 (is)
AU (1)	AU2004209447A1 (is)
BR (1)	BRPI0406957A (is)
CA (1)	CA2513409A1 (is)
CL (1)	CL2004000182A1 (is)
CR (1)	CR7932A (is)
EA (1)	EA200501253A1 (is)
EC (1)	ECSP055945A (is)
GT (1)	GT200400013A (is)
HR (1)	HRP20050659A2 (is)
IS (1)	IS7936A (is)
MA (1)	MA27652A1 (is)
MX (1)	MXPA05007562A (is)
NL (1)	NL1025404C2 (is)
NO (1)	NO20054082L (is)
OA (1)	OA12980A (is)
PE (1)	PE20040946A1 (is)
PL (1)	PL379009A1 (is)
TN (1)	TNSN05190A1 (is)
TW (1)	TWI260223B (is)
UY (1)	UY28178A1 (is)
WO (1)	WO2004069837A1 (is)
ZA (1)	ZA200506255B (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003257145B2 (en) *	2002-08-02	2008-11-13	Merck Sharp & Dohme Corp.	Substituted furo (2,3-b) pyridine derivatives
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) *	2003-04-23	2004-10-28	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) *	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
EP1622876A1 (en) *	2003-05-07	2006-02-08	Pfizer Products Inc.	Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) *	2003-05-09	2004-11-11	Pfizer Inc	Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7232823B2 (en) *	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) *	2003-07-30	2005-02-03	Pfizer Inc	Imidazole compounds and uses thereof
US20050043327A1 (en) *	2003-08-21	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7151097B2 (en) *	2003-11-07	2006-12-19	Pfizer Inc.	Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
WO2005049615A1 (en) *	2003-11-21	2005-06-02	Pfizer Products Inc.	Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
US7649002B2 (en)	2004-02-04	2010-01-19	Pfizer Inc	(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
EP1890767A2 (en) *	2005-05-27	2008-02-27	Pfizer Products Inc.	Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
AU2006253842A1 (en)	2005-06-02	2006-12-07	Glenmark Pharmaceuticals S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2006131807A1 (en) *	2005-06-06	2006-12-14	Pfizer Products Inc.	Preparation of 3-amino-4,5-disubstituted-pyrazole derivatives
EP2308840A1 (en)	2005-06-30	2011-04-13	Prosidion Limited	GPCR agonists
JP4847275B2 (ja) *	2005-10-21	2011-12-28	田辺三菱製薬株式会社	ピラゾロ［１，５−ａ］ピリミジン化合物
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
CA2642922C (en)	2006-02-23	2011-08-02	Pfizer Limited	Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
TW201345908A (zh) *	2006-07-05	2013-11-16	Mitsubishi Tanabe Pharma Corp	吡唑并〔１，５-ａ〕嘧啶化合物
JP2010509392A (ja)	2006-11-13	2010-03-25	ファイザー・プロダクツ・インク	ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
KR100808241B1 (ko) *	2006-11-21	2008-03-03	윤성화	Ｃｂ1에 길항 활성을 갖는 1ｈ-파이라졸-3-옥심카바메이트화합물 유도체
US8404896B2 (en)	2006-12-01	2013-03-26	Bristol-Myers Squibb Company	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
EP2114936A1 (en)	2007-01-04	2009-11-11	Prosidion Limited	Piperidine gpcr agonists
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
PE20081849A1 (es)	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
ES2373181T3 (es)	2007-01-04	2012-02-01	Prosidion Ltd	Agonistas de gpcr de piperidina.
PE20090142A1 (es) *	2007-04-11	2009-02-19	Merck & Co Inc	Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
JP4837701B2 (ja) *	2007-04-20	2011-12-14	田辺三菱製薬株式会社	医薬組成物
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
JP2010043063A (ja)	2008-05-09	2010-02-25	Agency For Science Technology & Research	川崎病の診断及び治療
US8592403B2 (en)	2008-08-06	2013-11-26	Pfizer Limited	Diazepine and diazocane compounds as MC4 agonists
WO2012138945A1 (en) *	2011-04-08	2012-10-11	Aestus Therapeutics, Inc.	Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
WO2014078802A1 (en)	2012-11-19	2014-05-22	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en)	2012-11-19	2014-10-28	Irm Llc	Compounds and compositions for the treatment of parasitic diseases
CA3089159A1 (en) *	2018-02-06	2019-08-15	Jiangsu Hengrui Medicine Co., Ltd.	Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
CN110551133A (zh) *	2019-07-23	2019-12-10	上海合全药业股份有限公司	叔丁基-5-(羟甲基)-7-氧杂-2-氮杂螺[3.5]壬烷-2-甲酸基酯的制法
CN112608316B (zh) *	2019-07-30	2022-10-21	厦门宝太生物科技股份有限公司	一种吡唑并三嗪类腺苷受体拮抗剂
EP4106876B1 (en)	2020-02-18	2025-09-17	Gilead Sciences, Inc.	Antiviral compounds
TWI794742B (zh)	2020-02-18	2023-03-01	美商基利科學股份有限公司	抗病毒化合物
TWI874791B (zh)	2020-02-18	2025-03-01	美商基利科學股份有限公司	抗病毒化合物
KR102923359B1 (ko)	2021-04-16	2026-02-05	길리애드 사이언시즈, 인코포레이티드	아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (en)	2021-08-18	2024-06-26	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US574491A (en) *		1897-01-05		Brake-beam
US3865824A (en)	1972-03-07	1975-02-11	Icn Pharmaceuticals	2-Aryl-7-substituted pyrazolo {8 1,5{i a{b {9 1,3,5-triazines
US3910907A (en)	1973-07-09	1975-10-07	Icn Pharmaceuticals	Pyrazolo(1,5-a)-1,3,5-triazines
US3995039A (en)	1975-05-27	1976-11-30	Merck & Co., Inc.	Pyrazolo [1,5-a] [1,3,5] triazines
CH635587A5 (fr)	1978-01-09	1983-04-15	Aron Sa	Derives amines de pyrazolo (1,5-a) s.triazine, therapeutiquement actifs et leurs procedes de preparation.
US4767858A (en)	1985-06-06	1988-08-30	Biomeasure, Incorporated	Anti-arthritic pyrazolo-triazine derivatives
US4734414A (en)	1985-06-06	1988-03-29	Biomeasure, Inc.	Anti-inflammatory and anti-arthritic pyrazolo-[1,5-a]-1,3,5-triazine derivatives, compositions, and method of use therefor
GB8613591D0 (en)	1986-06-04	1986-07-09	Roussel Lab Ltd	Chemical compounds
ES2037739T3 (es)	1986-10-22	1993-07-01	Ciba-Geigy Ag	Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo.
US4824834A (en)	1986-10-31	1989-04-25	Otsuka Pharmaceutical Company, Limited	Pyrazolotriazine compounds
AU611437B2 (en)	1987-05-29	1991-06-13	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5051518A (en)	1987-05-29	1991-09-24	Ortho Pharmaceutical Corporation	Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
JPH0276880A (ja)	1988-06-16	1990-03-16	Sankyo Co Ltd	悪液質改善治療剤
CA1330079C (en)	1988-10-13	1994-06-07	Michihiko Tsujitani	Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
JP2691317B2 (ja)	1989-08-25	1997-12-17	株式会社大塚製薬工場	４―ヒドロキシ―８―（３―低級アルコキシ―４―フェニルスルフィニルフェニル）ピラゾロ〔１，５―ａ〕―１，３，５―トリアジン光学活性体の塩類及びその製造方法
PH27357A (en)	1989-09-22	1993-06-21	Fujisawa Pharmaceutical Co	Pyrazole derivatives and pharmaceutical compositions comprising the same
GB2244487B (en)	1990-05-29	1994-02-02	Ici Plc	Azole derivatives
US5356894A (en)	1990-05-29	1994-10-18	Rodney Peter W	Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
FR2665898B1 (fr)	1990-08-20	1994-03-11	Sanofi	Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5420128A (en)	1990-10-09	1995-05-30	Otsuka Pharmaceutical Co., Ltd.	Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor
GB9111130D0 (en)	1991-05-23	1991-07-17	Ici Plc	Azole derivatives
GB9111131D0 (en)	1991-05-23	1991-07-17	Ici Plc	Heterocyclic compounds
GB9125002D0 (en)	1991-11-25	1992-01-22	Ici Plc	Azole derivatives
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5571813A (en)	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
FR2714057B1 (fr)	1993-12-17	1996-03-08	Sanofi Elf	Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en)	1994-07-15	1997-01-21	Eli Lilly And Company	Cannabinoid receptor antagonists
FR2741621B1 (fr)	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr)	1995-12-08	1999-10-22	Sanofi Sa	Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6124289A (en)	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
HU229024B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
US6060478A (en)	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
JP2001508799A (ja)	1997-01-21	2001-07-03	スミスクライン・ビーチャム・コーポレイション	新規カンナビノイド受容体モジュレータ
FR2758723B1 (fr)	1997-01-28	1999-04-23	Sanofi Sa	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2761266B1 (fr)	1997-03-28	1999-07-02	Sanofi Sa	Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
IL137019A (en)	1998-01-28	2010-11-30	Du Pont Pharm Co	2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
US6194410B1 (en)	1998-03-11	2001-02-27	Hoffman-La Roche Inc.	Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6509338B1 (en)	1998-06-22	2003-01-21	Bristol-Myers Squibb Company	Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists
IL141769A0 (en)	1998-09-11	2002-03-10	Aventis Pharma Sa	Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr)	1998-09-11	2000-11-17	Aventis Pharma Sa	Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr)	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
EP1218381B1 (en)	1999-09-30	2006-12-06	Neurogen Corporation	AMINO SUBSTITUTED PYRAZOLO¬1,5-a\|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a\|-1,3,5-TRIAZINES
JP2003510325A (ja)	1999-09-30	2003-03-18	ニューロジェン・コーポレーション	ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
FR2799124B1 (fr)	1999-10-01	2004-08-13	Sanofi Synthelabo	Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
MXPA02005101A (es)	1999-10-18	2003-09-25	Alexipharma Inc	Derivados de indol canabimimeticos.
JP2003512357A (ja)	1999-10-18	2003-04-02	ユニバーシティオブコネチカット	カンナビノイドレセプタ拮抗物質としてのピラゾール誘導体
FR2800375B1 (fr)	1999-11-03	2004-07-23	Sanofi Synthelabo	Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
FR2800372B1 (fr)	1999-11-03	2001-12-07	Sanofi Synthelabo	Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
AU2001233144A1 (en)	2000-01-31	2001-08-07	The University Of Kentucky Research Foundation	Triazines as appetite suppressor
FR2804604B1 (fr)	2000-02-09	2005-05-27	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6653304B2 (en)	2000-02-11	2003-11-25	Bristol-Myers Squibb Co.	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6479479B2 (en)	2000-03-03	2002-11-12	Aventis Pharma S.A.	Azetidine derivatives, their preparation and pharmaceutical compositions containing them
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en)	2000-03-03	2002-03-12	Aventis Pharma S.A.	Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
UA74367C2 (uk)	2000-03-23	2005-12-15	Сольве Фармас'Ютікалз Б.В.	ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
FR2809621B1 (fr)	2000-05-12	2002-09-06	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
US20020019421A1 (en)	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
FR2814678B1 (fr) *	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en)	2000-10-04	2002-07-11	Odile Piot-Grosjean	Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
HUP0303653A3 (en)	2000-12-28	2006-05-29	Ono Pharmaceutical Co	Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
IL157615A0 (en)	2001-03-13	2004-03-28	Bristol Myers Squibb Co	4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
ATE284872T1 (de)	2001-03-22	2005-01-15	Solvay Pharm Bv	4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
ITMI20011483A1 (it)	2001-07-11	2003-01-11	Res & Innovation Soc Coop A R	Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
WO2003007887A2 (en)	2001-07-20	2003-01-30	Merck & Co., Inc.	Substituted imidazoles as cannabinoid receptor modulators
FR2829027A1 (fr)	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr)	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
EP1421077A4 (en)	2001-08-31	2004-11-17	Univ Connecticut	NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS
TWI231757B (en)	2001-09-21	2005-05-01	Solvay Pharm Bv	1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CN1529595A (zh)	2001-09-21	2004-09-15	��ҩ��޹�˾	具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
AU2002333852B2 (en)	2001-09-21	2006-07-13	Solvay Pharmaceuticals B.V.	Novel 4,5-dihydro-1H-pyrazole derivativeshaving CB1-antagonistic activity
US6509367B1 (en)	2001-09-22	2003-01-21	Virginia Commonwealth University	Pyrazole cannabinoid agonist and antagonists
JP2005532982A (ja)	2001-09-24	2005-11-04	バイエル・フアーマシユーチカルズ・コーポレーシヨン	肥満の処置のためのピロール誘導体の製造及び使用
UY27450A1 (es)	2001-09-24	2003-04-30	Bayer Corp	Preparación y uso de derivados de imidazol para el tratamiento de la obesidad
JP2005504100A (ja)	2001-09-24	2005-02-10	バイエル・フアーマシユーチカルズ・コーポレーシヨン	肥満の治療のための１，５，６，７−テトラヒドロピロロ［３，２−ｃ］ピリジン誘導体の製造法および使用
SE0104330D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104332D0 (sv)	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
US20030139386A1 (en)	2001-12-21	2003-07-24	Sophie Cote	Pharmaceutical compositions based on azetidine derivatives
US20050171161A1 (en)	2002-03-06	2005-08-04	Fong Tung M.	Method of treatment or prevention of obesity
EP1485385B1 (en)	2002-03-07	2005-08-17	SmithKline Beecham Corporation	Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
JP3813152B2 (ja)	2002-03-12	2006-08-23	メルクエンドカムパニーインコーポレーテッド	置換アミド類
AR038966A1 (es)	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
US7423067B2 (en)	2002-03-26	2008-09-09	Merck & Co., Inc.	Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
ES2192494B1 (es)	2002-03-27	2005-02-16	Consejo Superior De Investigaciones Cientificas	Derivados de 1,2,4-triazol con propiedades cannabinoides.
FR2837706A1 (fr)	2002-03-28	2003-10-03	Sanofi Synthelabo	Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
AU2003225964B2 (en)	2002-03-28	2008-11-20	Merck Sharp & Dohme Corp.	Substituted 2,3-diphenyl pyridines
US20050154202A1 (en)	2002-04-05	2005-07-14	Hagmann William K.	Substituted aryl amides
FR2838439B1 (fr)	2002-04-11	2005-05-20	Sanofi Synthelabo	Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
WO2003086288A2 (en)	2002-04-12	2003-10-23	Merck & Co., Inc.	Bicyclic amides
US6825209B2 (en)	2002-04-15	2004-11-30	Research Triangle Institute	Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ES2287476T3 (es)	2002-05-10	2007-12-16	Smithkline Beecham Corporation	Pirazolopirimidinas sustituidas.
CA2494011A1 (en)	2002-08-02	2004-02-12	Sdgi Holdings, Inc.	Systems and techniques for illuminating a surgical space
UA80295C2 (en)	2002-09-06	2007-09-10	Biogen Inc	Pyrazolopyridines and using the same
MXPA05004115A (es)	2002-10-18	2005-06-22	Pfizer Prod Inc	Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
TWI290500B (en) *	2004-12-14	2007-12-01	Arima Optoelectronics Corp	Laser dicing apparatus for a silicon wafer and dicing method thereof

2004
- 2004-01-21 US US10/763,105 patent/US7329658B2/en not_active Expired - Fee Related
- 2004-01-26 HR HR20050659A patent/HRP20050659A2/hr not_active Application Discontinuation
- 2004-01-26 JP JP2006500314A patent/JP4018736B2/ja not_active Expired - Fee Related
- 2004-01-26 OA OA1200500215A patent/OA12980A/en unknown
- 2004-01-26 MX MXPA05007562A patent/MXPA05007562A/es unknown
- 2004-01-26 EA EA200501253A patent/EA200501253A1/ru unknown
- 2004-01-26 CN CNA2004800091255A patent/CN1768061A/zh active Pending
- 2004-01-26 PL PL379009A patent/PL379009A1/pl not_active Application Discontinuation
- 2004-01-26 CA CA002513409A patent/CA2513409A1/en not_active Abandoned
- 2004-01-26 AU AU2004209447A patent/AU2004209447A1/en not_active Abandoned
- 2004-01-26 AP AP2005003368A patent/AP2005003368A0/xx unknown
- 2004-01-26 WO PCT/IB2004/000269 patent/WO2004069837A1/en not_active Ceased
- 2004-01-26 KR KR1020057014432A patent/KR20050099531A/ko not_active Abandoned
- 2004-01-26 EP EP04705138A patent/EP1592691A1/en not_active Withdrawn
- 2004-01-26 BR BR0406957-9A patent/BRPI0406957A/pt not_active IP Right Cessation
- 2004-02-03 PE PE2004000124A patent/PE20040946A1/es not_active Application Discontinuation
- 2004-02-03 CL CL200400182A patent/CL2004000182A1/es unknown
- 2004-02-04 NL NL1025404A patent/NL1025404C2/nl not_active IP Right Cessation
- 2004-02-04 UY UY28178A patent/UY28178A1/es not_active Application Discontinuation
- 2004-02-05 AR ARP040100365A patent/AR043038A1/es unknown
- 2004-02-05 TW TW093102638A patent/TWI260223B/zh not_active IP Right Cessation
- 2004-02-06 GT GT200400013A patent/GT200400013A/es unknown
2005
- 2005-07-11 IS IS7936A patent/IS7936A/is unknown
- 2005-08-02 EC EC2005005945A patent/ECSP055945A/es unknown
- 2005-08-04 ZA ZA200506255A patent/ZA200506255B/en unknown
- 2005-08-04 CR CR7932A patent/CR7932A/es not_active Application Discontinuation
- 2005-08-05 TN TNP2005000190A patent/TNSN05190A1/fr unknown
- 2005-08-05 MA MA28421A patent/MA27652A1/fr unknown
- 2005-09-02 NO NO20054082A patent/NO20054082L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ECSP055945A (es)	2006-01-27
JP4018736B2 (ja)	2007-12-05
US20040157839A1 (en)	2004-08-12
EA200501253A1 (ru)	2006-02-24
NL1025404A1 (nl)	2004-08-09
TWI260223B (en)	2006-08-21
GT200400013A (es)	2004-12-16
AP2005003368A0 (en)	2005-09-30
AR043038A1 (es)	2005-07-13
AU2004209447A1 (en)	2004-08-19
ZA200506255B (en)	2006-05-31
TW200423942A (en)	2004-11-16
TNSN05190A1 (fr)	2007-06-11
NL1025404C2 (nl)	2005-03-14
BRPI0406957A (pt)	2006-01-03
CN1768061A (zh)	2006-05-03
JP2006517203A (ja)	2006-07-20
NO20054082L (no)	2005-11-04
CA2513409A1 (en)	2004-08-19
CR7932A (es)	2005-09-16
NO20054082D0 (no)	2005-09-02
AU2004209447A8 (en)	2004-08-19
HRP20050659A2 (en)	2006-02-28
MXPA05007562A (es)	2005-09-21
PE20040946A1 (es)	2005-01-01
US7329658B2 (en)	2008-02-12
OA12980A (en)	2006-10-13
WO2004069837A1 (en)	2004-08-19
PL379009A1 (pl)	2006-06-26
MA27652A1 (fr)	2005-12-01
EP1592691A1 (en)	2005-11-09
CL2004000182A1 (es)	2005-01-07
UY28178A1 (es)	2004-09-30
KR20050099531A (ko)	2005-10-13

Publication	Publication Date	Title
IS7936A (is)	2005-07-11	Pýrasóló[1,5-A][1,3,5]tríasín afleiður sem kannabinóíð viðtaka bindlar
ATE360632T1 (de)	2007-05-15	Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
NO20053955D0 (no)	2005-08-25	Pyrazolo [1,5-A] pyrimidinderivater
IS7314A (is)	2004-06-16	5,6-díarýl-pýrasín-2-amíðafleiður sem cb1 mótlyf
IS8472A (is)	2006-05-18	Tríasól afleiður sem þvagstemmuvaka mótlyf
NO20054330D0 (no)	2005-09-20	8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
DK1797099T3 (da)	2010-11-29	Piperidinylamino-thieno[2,3-D]pyrimidinforbindelser
IS8355A (is)	2006-03-16	Bísýklískar [3.1.0] afleiður sem hindra glýsín flutningsmiðla
NO20053748D0 (no)	2005-08-04	Pyrrolopyridazinderivater.
ATE387438T1 (de)	2008-03-15	Neue 1,2,4-triazolverbindung
IS8226A (is)	2006-01-11	3-útskipt 5,6-díarýl-pýrasín-2-karboxamíð og -2-súlfónamíðafleiður sem CB1 stillar
IS2843B (is)	2013-08-15	Pýrróló[3,4-c] pýrasólafleiður virkar sem kínasahindrar
DE602004021572D1 (de)	2009-07-30	SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE
DE60221301D1 (de)	2007-08-30	Klappsitz für Hecktür
IL182697A0 (en)	2007-09-20	Halogen substituted benzodiazepine derivatives
SI1626964T1 (sl)	2009-06-30	Novi benzimidazolni derivati
PL377609A1 (pl)	2006-02-06	Pochodne indazolu jako antagoniści CRF
ZA200506744B (en)	2006-06-28	PyrazoloÄ1,5-AÜpyrimidine derivatives
IL173911A0 (en)	2006-07-05	Imidazole derivatives
IL172821A0 (en)	2006-06-11	Imidazole derivatives iii
IL173347A0 (en)	2006-06-11	7-SUBSTITUTED 3-NITRO-PYRAZOLO[1,5-a] PYRIMIDINES
HU0300283D0 (en)	2003-03-28	New 2,3-substituted benzodiazepine derivatives
HU0400338D0 (en)	2004-04-28	New substituted benzodiazepine derivatives
IS8330A (is)	2006-02-27	2-Metoxýmetýl-3-(3,4-díklórófenýl)-8-asabísýkló[3.2.1]oktan-tartrasölt